Lv7
3760 积分 2023-06-12 加入
752-P: Efficacy and Safety of Bofanglutide (GZR18), a Biweekly GLP-1RA, Compared with Semaglutide in Chinese Patients with T2D
1天前
已关闭
Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity
16天前
已完结
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
19天前
已完结
Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial
19天前
已完结
Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial
19天前
已完结
GLP-1受体激动剂临床应用专家指导意见
23天前
已完结
Pharmacokinetics, pharmacodynamics, safety, and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in Japanese volunteers with iron-deficiency anemia
1个月前
已完结
Mazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m2 but without diabetes: A phase 2 randomized controlled trial
1个月前
已完结
Mazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m2 but without diabetes: A phase 2 randomized controlled trial
1个月前
已完结
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
2个月前
已完结
皖公网安备34019202002308
